ArticleFrontiers in microbiology2026
GII.23/24/25 noroviruses recognize glycans via a conventional glycan-binding site.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human noroviruses (HuNoVs) are genetically diverse RNA viruses that cause acute gastroenteritis, with genogroup II (GII) accounting for over 90% of global infections. Glycans, particularly histo-blood group antigens (HBGAs), have been identified as attachment factors or receptors for HuNoVs infection. However, the glycan-binding receptors of the later-identified GII genotypes GII.23/24/25 remain elusive. Methods: We used saliva- and glycan-based ELISA assays to identify the binding spectra of GII.23/24/25 strains. We also solved the crystal structures of their P domains, including the GII.25 P domain in complex with the H disaccharide. Single-point mutagenesis was performed to identify key residues involved in glycan binding. Results: The P domains of GII.24 and GII.25 can recognize multiple types of saliva samples, including both A/B/O secretor and nonsecretor individuals. In contrast, GII.23 primarily binds to B secretor saliva samples. Furthermore, GII.23/24 P domains are able to interact with the H disaccharide, whereas GII.25 exhibits binding affinity for both H disaccharide and B trisaccharide. Crystal structures of GII.23/24/25 P domains revealed high structural similarity, and the complex of GII.25 P domains with H disaccharide was resolved. Single-point mutagenesis identified N352, R353, D382, G443, G444, and H445 as critical residues for H disaccharide binding in GII.25 P domain, while A351 determines glycan-binding specificity. Discussion: Our findings demonstrate that GII.23/24/25 exhibit glycan-binding patterns similar to most other GII HuNoV genotypes. The structural insights provide a better understanding of virus-host evolution and inform the development of therapeutic strategies against HuNoVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.